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ABSTRACT 
Objective: Objective of the present investigation was to enhance the solubility and dissolution rate of poorly water-soluble drug lornoxicam using 
liquisolid technique with comparative determination of in vitro release profile of liquisolid compacts and conventional formulation of lornoxicam. 
Methods: Formulation was prepared by a liquisolid technique using different drug concentration in a liquid vehicle and different carrier/coating 
ratio. Prepared liquisolid compact was evaluated for Fourier transform infrared (FTIR) spectra analysis, differential scanning calorimetry (DSC), X-
ray diffraction (P-XRD), scanning electron microscopy (SEM) and in vitro dissolution study. 
Results: The result showed that liquisolid compacts of lornoxicam displayed significantly higher drug release rate as compared to pure drug and 
conventional tablet prepared. The results of both DSC and X-ray crystallography indicated loss of crystallinity of the drug upon formulated into the 
liquisolid compact.  
Conclusion: Dissolution rate of the drug from liquisolid compacts was affected by changing the drug concentration and excipient ratio. The 
liquisolid technique appeared to be a promising approach for improving the dissolution of poorly soluble drug lornoxicam. 
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The increased emergence of poorly water-soluble active compounds 
presents specific obstacles for the development of both immediate 
release and modified release dosage forms. The challenge for poorly 
water-soluble drugs is to enhance the rate of dissolution [1]. Various 
techniques have been used to formulate the oral drug delivery 
system that would enhance the dissolution profile and in turn, the 
absorption efficiency of the water-insoluble drug. Among them, the 
liquisolid compacts technique is one of the most promising and a 
new technique which promotes dissolution rate of water-insoluble 
drugs [2]. The term “Liquisolid systems” refers to immediate or 
sustained-release tablets or capsules that are prepared using the 
technique described under liquisolid systems, combined with the 
inclusion of appropriate adjuvants required for tableting or 
encapsulation, such as disintegrant for immediate release and 
binders for sustained release action [3]. In the liquisolid system, the 
liquid portion is a drug suspension, liquid drug, or drug solution 
made in suitable non-volatile liquid vehicles [4]. The present 
research involves enhancement of the solubility and dissolution rate 
of poorly water-soluble drug lornoxicam using the liquisolid 
technique with comparative determination of in vitro release profile 
of liquisolid compacts and conventional formulation of lornoxicam. 
MATERIALS AND METHODS 
Materials 
Lornoxicam (Cirex Pharmaceuticals Ltd. Andhra Pradesh, India), 
PEG 400 (Research Lab, Mumbai, India), Polysorbate 80 (Research 
Lab, Mumbai, India), Propylene glycol (Finer chem. Ltd. Ahmedabad, 
India), Avicel PH200 and 102 (Microcrystalline cellulose) (Maple 
Biotech Pvt. Ltd Pune, India), Florite® R (Calcium Silicate) (Tomita 
Pharmaceutical Tokushima, Japan), Neusilin US2, (Fuji Chemical 
Industry Co., Ltd), Lactose (Research Lab, Mumbai, India), 
Crospovidone, PVPK-30 (BASF, Germany). 
Solubility studies 
The drug content was determined using double beam UV-
spectrophotometer (UV 1800 Shimadzu) at 375 nm. The results were 
extrapolated to determine the solubility (mg/ml) of lornoxicam in its 
saturated solution with the solvent under investigation [3]. 
Determination of optimal flowable liquid retention potential (Φ 
value) for carrier and coating material 
The optimal flowable liquid retention potential of the carrier (AvicelΦ) 
and coating (Florite R) material in a liquid vehicle was calculated 
based on the angle of slide measurement θ [5, 6]. The calculated Φ 
value was plotted against the corresponding angle of slide θ. The Φ 
value corresponding to an angle of slide 33° represented the flowable 
liquid retention potential (Φ value) of powder excipients [7]. 
Preparation of liquisolid compact 
Lornoxicam was dispersed in Polyethylene glycol 400 to make 10–
50% w/w solutions (denoted as LS-1 to LS-6). A carrier material 
containing Avicel PH 200 was added to the liquid medication 
containing the drug and PEG 400 under continuous mixing in a 
mortar. Further addition of coating material containing Florite R 
converted the damp mass into a free-flowing powder at a fixed 
carrier: coating ratio 20:1. Depending upon the type of vehicle in the 
formulation, different liquid load factors were employed in liquisolid 
preparations. Different carrier: coating ratio of Avicel PH 200 and 
Florite R were also used to prepare different liquisolid formulation. 
liquisolid formulation LS-N is prepared using Neusilin US2 as a 
carrier and Florite R as a coating material. The high liquid loading 
capacity of this Neusilin US2 may be explained by its extremely high 
specific surface area of 339±1 m2
Determination of flow properties 
/g as well as its good flow and 
tableting properties. Finally, 5% w/w of crospovidone as a super 
disintegrant and 3% w/w PVP K-30 as a binder were added in the 
above powder blend. Table 1 denotes the key formulation 
characteristics of lornoxicam liquisolid compacts with different drug 
concentration and different excipient ratio respectively [8]. 
Precompression studies of the prepared liquisolid powder 
system 
The flowability of the liquisolid formulation can be evaluated by using 
parameters such as the angle of repose, carr’s index and hausner’s ratio. 
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Table 1: Key formulation characteristics of lornoxicam liquisolid compacts 
Liquisolid formulation Drug conc. in liquid vehicle R L Carrier (mg) f Coat (mg) Unit dose weight (mg) 
LS-1 10 20 0.139 576 28 755 
LS-2 15 20 0.139 381.3 19 500.6 
LS-3 20 20 0.139 288 14 377 
LS-4 30 20 0.139 187 9 244.8 
LS-5 40 20 0.139 144 7 188.6 
LS-6 50 20 0.139 115.3 5.7 151 
LS-N 30 20 0.869 65 3.3 103 
 
FTIR spectra analysis 
FTIR study was conducted to check compatibility between drug and 
excipients. Infrared spectrum of lornxicam, excipients, a drug with 
different excipients, physical mixture and the final liquisolid 
formulation was determined on FTIR Spectrophotometer (I. R 
Prestige-21 Shimadzu) using KBr dispersion method. 
DSC analysis 
Thermograms of the sample (lornoxicam and liquisolid system) 
were recorded on a DSC (SDT Q600 V20.9 Build 20). Thermal 
behavior of the samples was investigated under a scanning rate of 
10 °C/min, covering a temperature range of 30-300 °C. 
P-XRD analysis 
X-ray diffractograms of lornoxicam, excipients, physical mixture and 
liquisolid formulation were performed by using Philips Analytical 
XRD (PW 3710) with a wavelength of 2.28970 °A. The scanning 
range was from 10-100 02θ. 
SEM studies 
The samples were fixed on aluminum stubs with double-sided tape, 
gold-coated sputter and examined in the scanning microscope (JSM 
5600 LV Joel Japan) using an accelerating voltage of 15 kV, at a 
working distance of 8 mm. 
Evaluation of liquisolid tablets 
Prepared liquisolid tablets were evaluated for weight variation, 
hardness, friability, disintegration time and content uniformity [9]. 
In vitro dissolution studies 
In vitro dissolution studies were performed for LS-1 to LS–6, pure 
lornoxicam drug and conventional tablet, using USP dissolution 
apparatus II and specification in the BP. 5 ml sample was withdrawn at 
time intervals of 5, 10, 15, 20, 30, 45 and 60 min. Drug content in each 
withdrawn sample was determined using double beam UV 
spectrophotometer at 375 nm. Mean values of triplicate measurement 
were plotted versus time. Similar procedure was performed using 
0.1N HCl and phosphate buffer pH 7.4 as a dissolution medium [10]. 
Stability study 
Stability testing was performed as per FDA and ICH Guidelines of 
new drug products. The tablets were packed in the blister pack and 
were stored at 38.6 °C/75% relative humidity for 3 mo. After this 
period, stored tablets were evaluated (to study the effect of ageing 
on lornoxicamliquisolid tablets) via a dissolution test. 
RESULT AND DISCUSSION 
Solubility studies 
Saturation solubility data for the lornoxicam is given in table 2. 
 
Table 2: Saturation solubility data for the lornoxicam 
Solvent Solubility (mg/ml) 
Propylene glycol 1.115 
Tween 80 4.77 
Glycerin 1.0385 
Polyethylene glycol 400 8.954 
Water 0.00728 
phosphate buffer pH 6.8 0.0189 
phosphate buffer pH 7.4 0.0137 
0.1N HCl 0.0079 
All readings are average±SD (n=3) 
 
 
Fig. 1: Relationship between the angle of slide θ and Φ-value for (A) Florite R and (B) Neusilin US2 
 
Determination of flowable liquid retention potential (Φ-value) 
for excipients 
Fig. 1 shows the relationship between the angle of the slide and the 
corresponding Φ-value of Florite®
Precompression studies of the prepared liquisolid powder system:  
 R and Neusilin US2 determined in 
PEG 400 [3, 4]. 
Determination of flow properties 
LS-4showed good flow properties therefore considered as a 
liquisolid system with acceptable flowability [11]. Result of the flow 
properties of lornoxicam liquisolid systems is given in table 3. 
Mokashi et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 6, 33-37 
 
35 
FTIR spectra analysis 
The spectrum of pure lornoxicam shows a characteristic peak at 
1733.2 due to C=O stretch, 3067.91 due to N-H stretch, 738.77 due 
to C-Cl stretch. Appearance of these peaks in the physical mixture 
and liquisolid formulation indicate the absence of chemical 
interaction between the drug and excipients [11]. FTIR spectral data 
is shown in fig. 2. 
 
Table 3: Flow properties of lornoxicam liquisolid system 
Liquisolid system Angle of repose (θ) Carr’s compressibility index (%) Hausner’s ratio 
LS-1 33.46±0.95 14.72±0.50 1.23±0.07 
LS-2 32.42±0.71 16.73±0.21 1.19±0.01 
LS-3 36.43±0.70 17.59±0.60 1.17±0.03 
LS-4 21.69±0.56 11.43±0.39 1.12±0.02 
LS-5 35.20±0.77 15.54±0.30 1.18±0.02 
LS-6 37.37±0.28 18.19±0.17 1.17±0.05 
LS-N 21.69±0.56 16.73±0.21 1.18±0.17 
 
 
Fig. 2: Overlain FTIR spectrum of (A) lornoxicam (B) Avicel PH 200 (C) Florite R (D) lornoxicam: PEG400: Avicel PH 200 (E) lornoxicam: 
PEG400: Avicel PH 200: Florite R (F) physical mixture (G) liquisolid powder system 
 
DSC analysis 
DSC thermograms as shown in fig. 3 for pure lornoxicam show a 
sharp exothermic peak at 218.5 °C corresponding to its melting 
temperature (Tm); such sharp exothermic peak signifies that 
lornoxicam was in the pure crystalline state. This characteristic 
sharp melting peak of lornoxicam completely disappeared in DSC 
thermograms of LS-4 liquisolid formulation and a broadened peak 
with markedly reduced intensity was observed at approximately 
115.5 °C [11]. 
 
 
Fig. 3: DSC plot of lornoxicam and liquisolid formulation (LS-4) 
 
P-XRD analysis 
The P-XRD result as shown in fig. 4 is agreed well with the thermal 
analysis data. Pure lornoxicam was clearly in the crystalline state as 
it showed sharp distinct peaks notably at 2θ diffraction angles of 
13.5 °, 24.3 °, 21.04 °, and 27.4 °. X-ray data supported the 
conclusion that the lornoxicam formed a solid solution within the 
carrier matrix [11]. 
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Fig. 4: Powder X-ray diffractograms of lornoxicam, physical mixture, liquisolid powder system, and Avicel PH 200 
 
SEM studies 
Fig. 5 displays SEM microphotographs of pure lornoxicam and 
liquisolid powder system. Pure lornoxicam appears to be crystals 
in nature as previously proven by DSC and XRD the particles 
consist of flat faces with sharp and well-defined edges. Further, 
the photomicrographs of the liquisolid powder system signify the 
complete disappearance of lornoxicam crystals, a fact that 




Fig. 5: SEM of (A) lornoxicam (2,000X), (B) liquisolid powder system (100X) and liquisolid powder system (250X) 
 
Evaluation of lornoxicam liquisolid tablets 
All prepared tablets complied with the pharmacopeial required 
specifications for the weight variation and friability. Results for 
hardness and weight variation, friability and disintegration time are 
represented in table 4. As the amount of Avicel goes on increasing, 
hardness also increases. With a decrease in R values, hardness was 
decreased [11]. This low hardness could be attributed to the less 
amount of added Avicel and poor compressibility of Florite R [7]. 
Microcrystalline cellulose has disintegration property, which could 
facilitate the disintegration of tablets and dissolution of drug [12]. 
The higher R values represent lead to a more uniform distribution of 
drug the drug by either adsorption onto or absorption into the 
carrier [7]. 
 
Table 4: Data for lornoxicam liquisolid tablets 
Liquisolid system Hardness (kg/cm2 Wt. Variation (%) ) Friability (%) Disintegration time (sec) % Drug content 
LS-1 3.1±0.28 0.52±0.76 0.15±0.05 66.95±1.34 96.46±0.32 
LS-2 3.3±0.24 0.57±0.32 0.19±0.05 75.12±0.55 96.07±0.33 
LS-3 3.5±0.41 1.32±1.16 0.13±0.10 75.12±0.55 97.38±1.57 
LS-4 4.3±0.52 0.41±0.70 0.15±0.05 29.30±0.43 99.03±0.27 
LS-5 4.8±0.32 0.26±0.32 0.16±0.11 28.84±1.34 99.03±0.27 
LS-6 4.6±0.28 1.84±0.41 0.15±0.05 66.95±0.97 98.05±1.39 
LS-N 4.27±0.86 3.96±1.52 0.10±0.04 28.4±0.80 98.36±0.39 
All readings are average±SD (n=3) 
 
In vitro dissolution studies 
All the liqusiolid compacts showed higher drug release than the 
conventional tablet and the pure drug. It was observed from the 
Fig.6 that LS-4 shows the highest drug release 100±0.57% 
release at 60 min. Result is shown in fig. 6. Liquisolid compact 
LS–N shows higher drug release than a conventional tablet and 
pure drug but slower drug release as compared to LS–4 
formulation this may be due to slower disintegration of LS–N as 
compared to LS-4. 
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Fig. 6: Percentage drug released from liquisolid compacts 
 
Stability study 
3 tablets from LS-4 series were kept at 38.6 °C/75% relative 
humidity for 3 mo. Dissolution rate was measured for the aged 
tablets. Result is shown in fig. 7, with a calculated similarity factor 
(f2 value) of 67.18 and dissimilarity factor (f1 value) of 5.7.  
 
 
Fig. 7: Dissolution profile of fresh v/s aged LS-4 tablets 
 
CONCLUSION 
It can be concluded from the observations that formulation LS–4 
optimally achieved the objectives of preparation of liquisolid compact 
of lornoxicam i.e. enhanced drug dissolution and solubility. The 
enhanced dissolution rate of lornoxicam from liquisolid tablets was 
due to an increase in wetting properties and surface area of drug 
particles available for dissolution. In this case, even though the drug is 
in a solid dosage form, it is held within the powder substrate in 
solution or in a solubilized, almost molecularly dispersed state, which 
contributes to the enhanced drug dissolution properties and the tablet 
properties were all within acceptable ranges. The results of both DSC 
and XRD suggested the loss of crystallinity of the drug upon liquisolid 
formulation indicating that the drug is held within the powder 
substrate in a solubilized state which contributed to the improvement 
in the dissolution rate and these results are supported by data from 
FTIR and SEM. Stability studies by means of dissolution testing 
showed that the liquisolid preparation produced were stable and not 
significantly affected by ageing. 
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